登录后查看消息通知
搜索
常见问题
消息
登录
首页
/
数据集
/
Cohort II: Frequency of Dose Reductions for patients receiving Gemcitabine and Irinotecan.
Cohort II: Frequency of Dose Reductions for patients receiving Gemcitabine and Irinotecan.
收藏
Figshare
2015-12-02 更新
2026-04-29 收录
化疗药物剂量
肿瘤治疗安全性
数据链接:
https://figshare.com/articles/dataset/_Cohort_II_Frequency_of_Dose_Reductions_for_patients_receiving_Gemcitabine_and_Irinotecan_/278670
数据链接
链接失效反馈
官方服务:
问题咨询
购买咨询
在线客服
NEW
资源简介:
1Defined as 98% or more of the targeted dose.
应用场景:
创建时间:
2015-12-02
相关数据集
Risk ratio of fatal adverse events by subgroup.
肿瘤治疗安全性
不良事件分析
NSCLC, non– small cell lung cancer; SCLC, small cell lung cancer; RR, risk ratio; PFS, progression-free survival; NA, not applicable.
NIAID Data Ecosystem
8
0
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
化疗药物剂量
联合用药临床研究
The purpose of this study is to determine a safe and maximum tolerable dose of Brivanib when combined with standard dose 5FU/LV and FOLFIRI.
NIAID Data Ecosystem
8
0
TABLE 2 from Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
肿瘤治疗安全性
药物不良反应监测
Frequency of treatment-related adverse events and laboratory abnormalities
Figshare
2023-06-28 更新
6
0
Additional file 4 of Decitabine in combination with fludarabine and cyclophosphamide as a lymphodepletion regimen followed by CD19/CD22 bispecific targeted CAR T-cell therapy significantly improves survival in relapsed/refractory B-ALL patients
肿瘤治疗安全性
不良事件分析
Additional file 4. Adverse Events.
DataCite Commons
2024-02-08 更新
8
0
Optimal intervals for follow-up cystoscopy in non-muscle invasive bladder cancer: a systematic review regarding oncological safety
膀胱癌
肿瘤治疗安全性
Improving efficiency of follow-up for non-muscle invasive bladder tumours (NMIBC) without risking disease progression through delays of recurrence diagnosis, is a highly relevant field of research. Th
DataCite Commons
2022-04-12 更新
7
0
© 2023-2026 上海数据发展科技有限责任公司 版权所有
沪ICP备17003045号-15
沪公网安备31010402336585号
热门搜索
社区交流群
科研交流群
商业服务
数据资源
寻源服务
数据采集
标注服务
数据产品
代理销售
数据领域
凭证登记
数据产品
介绍推广